Cited by 423Retinal Diseases and TreatmentsRetinal Imaging and AnalysisDiabetes Management and Research

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Prevalence of and Risk Factors for Diabetic Macular Edema in the United States

Open access

Abstract

IMPORTANCE: Diabetic macular edema (DME) is a leading cause of vision loss in persons with diabetes mellitus. Although there are national estimates for the prevalence of diabetic retinopathy and its risk factors among persons with diabetes, to our knowledge, no comparable estimates are available for DME specifically. OBJECTIVES: To estimate the prevalence of DME in the US population and to identify associated risk factors. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional analysis of 1038 participants aged 40 years or older with diabetes and valid fundus photographs in the 2005 to 2008 National Health and Nutrition Examination Survey. MAIN OUTCOMES AND MEASURES: The overall prevalence of DME and its prevalence according to age, race/ethnicity, and sex. RESULTS: Of the 1038 persons with diabetes analyzed for this study, 55 had DME, for an overall weighted prevalence of 3.8% (95% CI, 2.7%-4.9%) or approximately 746, 000 persons in the US 2010 population aged 40 years or older. We identified no differences in the prevalence of DME by age or sex. Multivariable logistic regression analysis showed that the odds of having DME were higher for non-Hispanic blacks than for non-Hispanic whites (odds ratio [OR], 2.64; 95% CI, 1.19-5.84; P = .02). Elevated levels of glycosylated hemoglobin A1c (OR, 1.47; 95% CI, 1.26-1.71 for each 1%; P < .001) and longer duration of diabetes (OR, 8.51; 95% CI, 3.70-19.54 for ≥ 10 vs <10 years; P < .001) were also associated with DME prevalence. CONCLUSIONS AND RELEVANCE: These results suggest a greater burden of DME among non-Hispanic blacks, individuals with high levels of hemoglobin A1c, and those with longer duration of diabetes. Given recent treatment advances in reducing vision loss and preserving vision in persons with DME, it is imperative that all persons with diabetes receive early screening; this recommendation is even more important for those at higher risk for DME.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaophthalmol.2014.2854

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. [14]Regeneron Pharmaceuticals Inc Regeneron and Bayer report positive one-year results from two phase 3 trials of EYLEA® (aflibercept) injection for the treatment of diabetic macular edema [press release] 2013 8 6 Regeneron Pharmaceuticals Inc Accessed October 8, 2013 website. http://investor.regeneron.com/releasedetail.cfm?ReleaseID=782911.

Cited by

Sorted by citations

Items 401–422 of 422

Metadata

Authors
Varma, R., Bressler, N. M., Doan, Q. V., Gleeson, M., Danese, M., Bower, J. K., Selvin, E., Dolan, C., Fine, J., Colman, S., & Turpcu, A.
Affiliations
  • University of Southern California (US)
  • Johns Hopkins University (US)
  • Outcomes Insights, Inc, Westlake Village, California
  • The Ohio State University (US)
  • Genentech (US)
Corresponding author
Varma, Rohit
Venue
JAMA Ophthalmology
Published
2014-11-01
Volume
132
Issue
11
Pages
1334
ISSN
2168-6165 (ISSN-L)
OpenAlex
W2075206985
Cited by
423
References
38
Citations by year
2026: 26 · 2025: 38 · 2024: 38 · 2023: 38 · 2022: 62 · 2021: 31 · 2020: 42 · 2019: 28 · 2018: 26 · 2017: 29 · 2016: 32 · 2015: 30 · 2014: 2
FWCI
29.07
Type
journal article
Language
en
Open access
Locations
  • JAMA Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Heart, Lung, and Blood Institute (T32HL007024)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
diabetic macular edema, prevalence, risk factors, diabetes mellitus, racial disparities, non-Hispanic blacks, HbA1c, diabetes duration, vision loss, diabetic retinopathy, vision screening
MeSH terms
Adult, Aged, Blood Glucose, Cross-Sectional Studies, Diabetic Retinopathy, Ethnicity, Female, Health Surveys, Glycated Hemoglobin, Humans, Macular Edema, Male, Middle Aged, Nutrition Surveys, Risk Factors, United States, Prevalence, Age Distribution, Sex Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review